Parvus Therapeutics Inc

Parvus Therapeutics Inc. is a privately held biopharmaceutical company developing NavacimsTM, a platform technology based on foundational research published in 2016 (Nature 530:434), to treat autoimmune diseases. Parvus mission is to shift the treatment paradigm toward Navacim-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus innovative approach has the potential to benefit millions of patients suffering from debilitating autoimmune diseases and other chronic inflammatory conditions. Parvus is advancing a pipeline of proprietary drug candidates for multiple autoimmune indications through preclinical development and into the clinical. Parvus leadership team is experienced in successful drug discovery, development, manufacturing, regulatory...

Parvus therapeutics inc operates in the Biotechnology research industry.

Parvus therapeutics inc's revenue is 11m - 100m

Parvus therapeutics inc has 11 - 50 employees.